{"ticker": {"uuid": "30c32009-371c-4d93-ab75-ec2de4550915", "symbol": "RO", "name": "Roche Holding AG", "exchange": "EBS", "country": "CH", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?", "summary": "In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce Labcorp's role as a major companion diagnostics provider while signaling management confidence in the busi", "url": "https://finance.yahoo.com/healthcare/articles/did-stronger-guidance-buybacks-oncology-054120115.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T05:41:20+00:00", "published_display": "12 Aug 2026 05:41", "sentiment": "positive", "sentiment_pct": 58, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.311, "duplicate_count": 1, "topics": ["Diagnostics", "Earnings", "Fda Approval", "Guidance", "Revenue Growth", "Share Buyback"]}, {"title": "Roche (SWX:ROG) Stock Fair Value Edges Higher As Analysts Weigh Pipeline Growth", "summary": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Roche Holding now sits on a refreshed fair value estimate of CHF 370.31, up from CHF 359.22. This gives you an updated reference point for where analysts see the stock's long term potential. This move lines up with recent research that highlights contrasting views on the company's pipeline, from optimism around giredestrant and 2027 catalysts to more cautious takes on how much upside is already captured in forecasts. Read on to see how these shifting assumptions shape the evolving narrat", "url": "https://finance.yahoo.com/markets/stocks/articles/roche-swx-rog-stock-fair-161250128.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:12:50+00:00", "published_display": "11 Aug 2026 16:12", "sentiment": "positive", "sentiment_pct": 83, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.207, "duplicate_count": 1, "topics": ["Discounted Cash Flow", "Pharma", "Price Target", "Price Target", "Upgrade Downgrade"]}, {"title": "REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?", "summary": "The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investmen", "url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:30:00+00:00", "published_display": "11 Aug 2026 14:30", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.192, "duplicate_count": 1, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Oncology", "Quarterly Results"]}, {"title": "ChemoMetec enters collaboration agreement with Roche Diagnostics", "summary": "Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today entered a collaboration agreement. The agreement covers the development of a connection kit between the Roche-owned Cedex\u00ae Bio Analyzer and the ChemoMetec-owned Xcytomatic\u00ae 30 (XM30) cell counting analyzer, as well as aspects of the subsequent commercialization of the connectivity solution. Roche will be ", "url": "https://finance.yahoo.com/healthcare/articles/chemometec-enters-collaboration-agreement-roche-103200914.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T10:32:00+00:00", "published_display": "10 Aug 2026 10:32", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.139, "duplicate_count": 1, "topics": ["Biotech", "Collaboration", "Diagnostics", "Pharma"]}, {"title": "Roche Stock Jumps as Morgan Stanley Sees Drug Breakout", "summary": "This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. The upgrade helped send Roche's U.S.-traded ADRs up about 2.2% to $57.38 during Friday's session. Morgan Stanley also swapped out AstraZeneca as its top pharmaceutical pick in favor of Roche, a clear sign the bank believes the company's next growth story is gaining momentum. Warning! GuruFocus has detected 7 Warning Signs ", "url": "https://finance.yahoo.com/healthcare/articles/roche-stock-jumps-morgan-stanley-193033041.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:30:33+00:00", "published_display": "07 Aug 2026 19:30", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.088, "duplicate_count": 1, "topics": ["Earnings Estimate", "Fda Approval", "Intrinsic Value", "Pharma", "Price Target", "Price Target"]}], "by_tier": {"direct": [{"title": "Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?", "summary": "In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce Labcorp's role as a major companion diagnostics provider while signaling management confidence in the busi", "url": "https://finance.yahoo.com/healthcare/articles/did-stronger-guidance-buybacks-oncology-054120115.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T05:41:20+00:00", "published_display": "12 Aug 2026 05:41", "sentiment": "positive", "sentiment_pct": 58, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.311, "duplicate_count": 1, "topics": ["Diagnostics", "Earnings", "Fda Approval", "Guidance", "Revenue Growth", "Share Buyback"]}, {"title": "Roche (SWX:ROG) Stock Fair Value Edges Higher As Analysts Weigh Pipeline Growth", "summary": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Roche Holding now sits on a refreshed fair value estimate of CHF 370.31, up from CHF 359.22. This gives you an updated reference point for where analysts see the stock's long term potential. This move lines up with recent research that highlights contrasting views on the company's pipeline, from optimism around giredestrant and 2027 catalysts to more cautious takes on how much upside is already captured in forecasts. Read on to see how these shifting assumptions shape the evolving narrat", "url": "https://finance.yahoo.com/markets/stocks/articles/roche-swx-rog-stock-fair-161250128.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:12:50+00:00", "published_display": "11 Aug 2026 16:12", "sentiment": "positive", "sentiment_pct": 83, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.207, "duplicate_count": 1, "topics": ["Discounted Cash Flow", "Pharma", "Price Target", "Price Target", "Upgrade Downgrade"]}, {"title": "REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?", "summary": "The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investmen", "url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T14:30:00+00:00", "published_display": "11 Aug 2026 14:30", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.192, "duplicate_count": 1, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Oncology", "Quarterly Results"]}, {"title": "ChemoMetec enters collaboration agreement with Roche Diagnostics", "summary": "Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today entered a collaboration agreement. The agreement covers the development of a connection kit between the Roche-owned Cedex\u00ae Bio Analyzer and the ChemoMetec-owned Xcytomatic\u00ae 30 (XM30) cell counting analyzer, as well as aspects of the subsequent commercialization of the connectivity solution. Roche will be ", "url": "https://finance.yahoo.com/healthcare/articles/chemometec-enters-collaboration-agreement-roche-103200914.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T10:32:00+00:00", "published_display": "10 Aug 2026 10:32", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.139, "duplicate_count": 1, "topics": ["Biotech", "Collaboration", "Diagnostics", "Pharma"]}, {"title": "Roche Stock Jumps as Morgan Stanley Sees Drug Breakout", "summary": "This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. The upgrade helped send Roche's U.S.-traded ADRs up about 2.2% to $57.38 during Friday's session. Morgan Stanley also swapped out AstraZeneca as its top pharmaceutical pick in favor of Roche, a clear sign the bank believes the company's next growth story is gaining momentum. Warning! GuruFocus has detected 7 Warning Signs ", "url": "https://finance.yahoo.com/healthcare/articles/roche-stock-jumps-morgan-stanley-193033041.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:30:33+00:00", "published_display": "07 Aug 2026 19:30", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.088, "duplicate_count": 1, "topics": ["Earnings Estimate", "Fda Approval", "Intrinsic Value", "Pharma", "Price Target", "Price Target"]}], "industry": [], "sector": []}, "total_fetched": 5, "total_unique": 5, "total_relevant": 5, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 5, "unique_stories": 5, "duplicates_removed": 0, "relevant_stories": 5, "current_evidence": 5, "direct_evidence": 5, "eodhd_articles": 5, "eodhd": {"configured": true, "status": "healthy", "calls_used": 165, "call_budget": 500, "budget_used_pct": 33.0, "requests_made": 33, "last_success_at": "2026-08-13T04:02:21.506529+00:00", "newest_seen_at": "2026-08-13T03:33:27+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3670, "unmapped_mentions": 1834}, "status": "healthy"}, "sentiment_summary": {"positive": 5, "negative": 0, "neutral": 0, "score": 63, "raw_score": 70, "total": 5, "evidence_count": 5, "effective_articles": 4.31, "direct_story_count": 5, "industry_story_count": 0, "sector_story_count": 0, "story_count": 5, "source_count": 1, "source_concentration": 1.0, "direct_share": 100, "dispersion": 11, "confidence": 68, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-12T05:41:20+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "analyst", "primary_label": "Analyst action", "confidence": 62, "events": [{"event": "analyst", "label": "Analyst action", "weight": 1.2, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.6, "count": 1}, {"event": "earnings", "label": "Earnings", "weight": 0.6, "count": 1}, {"event": "general", "label": "Market update", "weight": 0.6, "count": 1}], "positive_events": 5, "negative_events": 0, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 5, "unique_stories": 5, "duplicates_removed": 0, "relevant_stories": 5, "current_evidence": 5, "direct_evidence": 5, "eodhd_articles": 5, "eodhd": {"configured": true, "status": "healthy", "calls_used": 165, "call_budget": 500, "budget_used_pct": 33.0, "requests_made": 33, "last_success_at": "2026-08-13T04:02:21.506529+00:00", "newest_seen_at": "2026-08-13T03:33:27+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3670, "unmapped_mentions": 1834}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 372.6, "latest_week": "2026-08-07", "one_week_move": 3.8, "four_week_move": 9.3, "twelve_week_move": 12.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.792563, "market_dynamics_buy_signal": false, "relative_strength": 5.452374, "fair_value_gap": 34.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.9394, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.8% over one week, +9.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "News confirmed by price", "tone": "positive", "classification": "confirmed_positive", "summary": "Constructive news tone is being confirmed by positive weekly price action.", "confidence": 69, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Analyst action", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 5}], "tiers": [{"label": "Direct company coverage", "count": 5}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Earnings", "count": 1}, {"label": "Market update", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "63/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "68/100", "tone": "neutral", "text": "4.31 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "News confirmed by price", "tone": "positive", "text": "Constructive news tone is being confirmed by positive weekly price action."}, {"label": "Primary event", "value": "Analyst action", "tone": "positive", "text": "62/100 classification confidence."}, {"label": "Company focus", "value": "5", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "11/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+3.8% over one week, +9.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?"}], "updated_at": "2026-08-13T04:03:45.043324+00:00", "detail_intelligence": {"headline": "News confirmed by price", "summary": "Constructive news tone is drawn from 5 fresh independent stories, including 5 company-specific items across 1 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 63, "display": "63", "tone": "positive", "note": "Constructive news tone"}, {"label": "Evidence confidence", "value": 68, "display": "68", "tone": "neutral", "note": "solid confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "5 direct stories"}, {"label": "Evidence agreement", "value": 89, "display": "89", "tone": "positive", "note": "11/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 54, "note": "4.31 effective stories"}, {"label": "Source breadth", "value": 20, "note": "1 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 75, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 89, "note": "cross-story consistency"}, {"label": "Source independence", "value": 0, "note": "lower publisher concentration"}], "freshness": 75, "source_independence": 0, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 1, "score": 65, "tone": "positive", "x": 683.2, "y": 107.7, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 774.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 1, "score": 61, "tone": "positive", "x": 820.6, "y": 115.0, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 2, "score": 83, "tone": "positive", "x": 866.4, "y": 74.9, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 1, "score": 58, "tone": "positive", "x": 912.2, "y": 120.4, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "683.2,107.7 820.6,115.0 866.4,74.9 912.2,120.4", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Improving", "tone": "positive", "recent_score": 70, "prior_score": 65, "delta": 5, "recent_count": 4, "prior_count": 1, "volume_delta": 3}, "freshness_buckets": [{"label": "Last 24 hours", "count": 1, "share": 20}, {"label": "1 to 3 days", "count": 3, "share": 60}, {"label": "4 to 7 days", "count": 1, "share": 20}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 5, "share": 100, "score": 70, "tone": "positive"}], "event_profile": [{"label": "Analyst action", "count": 2, "share": 40, "score": 78, "tone": "positive"}, {"label": "Earnings", "count": 1, "share": 20, "score": 82, "tone": "positive"}, {"label": "Market update", "count": 1, "share": 20, "score": 61, "tone": "positive"}, {"label": "Capital return", "count": 1, "share": 20, "score": 58, "tone": "positive"}], "topics": [{"label": "Price Target", "count": 4, "share": 80}, {"label": "Pharma", "count": 3, "share": 60}, {"label": "Fda Approval", "count": 3, "share": 60}, {"label": "Earnings", "count": 2, "share": 40}, {"label": "Diagnostics", "count": 2, "share": 40}, {"label": "Biotech", "count": 2, "share": 40}, {"label": "Upgrade Downgrade", "count": 1, "share": 20}, {"label": "Share Buyback", "count": 1, "share": 20}, {"label": "Revenue Growth", "count": 1, "share": 20}, {"label": "Quarterly Results", "count": 1, "share": 20}], "supporting": [{"label": "Direct evidence", "text": "5 current stories are mapped specifically to RO."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 89/100, indicating a comparatively coherent tape."}, {"label": "Price response", "text": "Constructive news tone is being confirmed by positive weekly price action."}], "tempering": [{"label": "Source breadth", "text": "Only 1 publisher currently contribute to the measured read."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?", "summary": "In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce Labcorp's role as a major companion diagnostics provider while signaling management confidence in the busi", "url": "https://finance.yahoo.com/healthcare/articles/did-stronger-guidance-buybacks-oncology-054120115.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T05:41:20+00:00", "published_display": "12 Aug 2026 05:41", "sentiment": "positive", "sentiment_pct": 58, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.316, "duplicate_count": 1, "topics": ["Diagnostics", "Earnings", "Fda Approval", "Guidance", "Revenue Growth", "Share Buyback"]}, "article_count": 5, "updated_at": "2026-08-13T01:57:21.913655+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 87.7, "label": "13 Feb 2026", "close": 359.05, "index": 100.0}, {"x": 77.5, "y": 76.3, "label": "20 Feb 2026", "close": 363.89, "index": 101.3}, {"x": 113.0, "y": 63.5, "label": "27 Feb 2026", "close": 369.31, "index": 102.9}, {"x": 148.5, "y": 129.7, "label": "06 Mar 2026", "close": 341.23, "index": 95.0}, {"x": 184.0, "y": 157.6, "label": "13 Mar 2026", "close": 329.4, "index": 91.7}, {"x": 219.5, "y": 204.2, "label": "20 Mar 2026", "close": 309.6, "index": 86.2}, {"x": 254.9, "y": 172.6, "label": "27 Mar 2026", "close": 323.0, "index": 90.0}, {"x": 290.4, "y": 151.4, "label": "03 Apr 2026", "close": 332.0, "index": 92.5}, {"x": 325.9, "y": 158.5, "label": "10 Apr 2026", "close": 329.0, "index": 91.6}, {"x": 361.4, "y": 151.0, "label": "17 Apr 2026", "close": 332.2, "index": 92.5}, {"x": 396.9, "y": 151.9, "label": "24 Apr 2026", "close": 331.8, "index": 92.4}, {"x": 432.4, "y": 164.2, "label": "01 May 2026", "close": 326.6, "index": 91.0}, {"x": 467.9, "y": 172.6, "label": "08 May 2026", "close": 323.0, "index": 90.0}, {"x": 503.4, "y": 151.9, "label": "15 May 2026", "close": 331.8, "index": 92.4}, {"x": 538.9, "y": 134.0, "label": "22 May 2026", "close": 339.4, "index": 94.5}, {"x": 574.4, "y": 140.6, "label": "29 May 2026", "close": 336.6, "index": 93.7}, {"x": 609.8, "y": 151.0, "label": "05 Jun 2026", "close": 332.2, "index": 92.5}, {"x": 645.3, "y": 146.7, "label": "12 Jun 2026", "close": 334.0, "index": 93.0}, {"x": 680.8, "y": 167.9, "label": "19 Jun 2026", "close": 325.0, "index": 90.5}, {"x": 716.3, "y": 127.9, "label": "26 Jun 2026", "close": 342.0, "index": 95.3}, {"x": 751.8, "y": 118.0, "label": "03 Jul 2026", "close": 346.2, "index": 96.4}, {"x": 787.3, "y": 130.2, "label": "10 Jul 2026", "close": 341.0, "index": 95.0}, {"x": 822.8, "y": 133.5, "label": "17 Jul 2026", "close": 339.6, "index": 94.6}, {"x": 858.3, "y": 85.5, "label": "24 Jul 2026", "close": 360.0, "index": 100.3}, {"x": 893.8, "y": 88.3, "label": "31 Jul 2026", "close": 358.8, "index": 99.9}, {"x": 929.3, "y": 55.8, "label": "07 Aug 2026", "close": 372.6, "index": 103.8}], "sentiment_points": [{"x": 681.7, "y": 124.5, "label": "19 Jun 2026", "score": 53}, {"x": 683.2, "y": 124.5, "label": "19 Jun 2026", "score": 53}, {"x": 683.4, "y": 124.5, "label": "19 Jun 2026", "score": 53}, {"x": 687.4, "y": 124.5, "label": "20 Jun 2026", "score": 53}, {"x": 687.6, "y": 124.5, "label": "20 Jun 2026", "score": 53}, {"x": 691.7, "y": 126.3, "label": "21 Jun 2026", "score": 52}, {"x": 696.3, "y": 126.3, "label": "22 Jun 2026", "score": 52}, {"x": 708.8, "y": 124.5, "label": "24 Jun 2026", "score": 53}, {"x": 709.1, "y": 124.5, "label": "24 Jun 2026", "score": 53}, {"x": 714.6, "y": 124.5, "label": "25 Jun 2026", "score": 53}, {"x": 718.3, "y": 128.2, "label": "26 Jun 2026", "score": 51}, {"x": 721.7, "y": 128.2, "label": "27 Jun 2026", "score": 51}, {"x": 737.4, "y": 128.2, "label": "30 Jun 2026", "score": 51}, {"x": 738.5, "y": 128.2, "label": "30 Jun 2026", "score": 51}, {"x": 742.7, "y": 128.2, "label": "01 Jul 2026", "score": 51}, {"x": 747.5, "y": 128.2, "label": "02 Jul 2026", "score": 51}, {"x": 752.1, "y": 128.2, "label": "03 Jul 2026", "score": 51}, {"x": 755.1, "y": 128.2, "label": "03 Jul 2026", "score": 51}, {"x": 766.1, "y": 126.3, "label": "05 Jul 2026", "score": 52}, {"x": 768.4, "y": 126.3, "label": "06 Jul 2026", "score": 52}, {"x": 769.3, "y": 126.3, "label": "06 Jul 2026", "score": 52}, {"x": 769.4, "y": 126.3, "label": "06 Jul 2026", "score": 52}, {"x": 771.7, "y": 124.5, "label": "06 Jul 2026", "score": 53}, {"x": 783.1, "y": 126.3, "label": "09 Jul 2026", "score": 52}, {"x": 786.2, "y": 130.0, "label": "09 Jul 2026", "score": 50}, {"x": 788.1, "y": 130.0, "label": "10 Jul 2026", "score": 50}, {"x": 790.6, "y": 130.0, "label": "10 Jul 2026", "score": 50}, {"x": 793.1, "y": 130.0, "label": "11 Jul 2026", "score": 50}, {"x": 795.4, "y": 130.0, "label": "11 Jul 2026", "score": 50}, {"x": 808.3, "y": 128.2, "label": "14 Jul 2026", "score": 51}, {"x": 814.2, "y": 124.5, "label": "15 Jul 2026", "score": 53}, {"x": 824.6, "y": 122.6, "label": "17 Jul 2026", "score": 54}, {"x": 839.6, "y": 122.6, "label": "20 Jul 2026", "score": 54}, {"x": 839.7, "y": 122.6, "label": "20 Jul 2026", "score": 54}, {"x": 840.2, "y": 122.6, "label": "20 Jul 2026", "score": 54}, {"x": 848.8, "y": 124.5, "label": "22 Jul 2026", "score": 53}, {"x": 850.4, "y": 124.5, "label": "22 Jul 2026", "score": 53}, {"x": 854.8, "y": 124.5, "label": "23 Jul 2026", "score": 53}, {"x": 863.5, "y": 124.5, "label": "25 Jul 2026", "score": 53}, {"x": 875.9, "y": 126.3, "label": "27 Jul 2026", "score": 52}, {"x": 878.1, "y": 126.3, "label": "27 Jul 2026", "score": 52}, {"x": 887.8, "y": 130.0, "label": "29 Jul 2026", "score": 50}, {"x": 889.6, "y": 130.0, "label": "30 Jul 2026", "score": 50}, {"x": 894.7, "y": 130.0, "label": "31 Jul 2026", "score": 50}, {"x": 904.7, "y": 130.0, "label": "02 Aug 2026", "score": 50}, {"x": 913.6, "y": 130.0, "label": "03 Aug 2026", "score": 50}, {"x": 924.8, "y": 126.3, "label": "06 Aug 2026", "score": 52}, {"x": 958.0, "y": 106.1, "label": "12 Aug 2026", "score": 63}], "price_path": "42.0,87.7 77.5,76.3 113.0,63.5 148.5,129.7 184.0,157.6 219.5,204.2 254.9,172.6 290.4,151.4 325.9,158.5 361.4,151.0 396.9,151.9 432.4,164.2 467.9,172.6 503.4,151.9 538.9,134.0 574.4,140.6 609.8,151.0 645.3,146.7 680.8,167.9 716.3,127.9 751.8,118.0 787.3,130.2 822.8,133.5 858.3,85.5 893.8,88.3 929.3,55.8", "sentiment_path": "681.7,124.5 683.2,124.5 683.4,124.5 687.4,124.5 687.6,124.5 691.7,126.3 696.3,126.3 708.8,124.5 709.1,124.5 714.6,124.5 718.3,128.2 721.7,128.2 737.4,128.2 738.5,128.2 742.7,128.2 747.5,128.2 752.1,128.2 755.1,128.2 766.1,126.3 768.4,126.3 769.3,126.3 769.4,126.3 771.7,124.5 783.1,126.3 786.2,130.0 788.1,130.0 790.6,130.0 793.1,130.0 795.4,130.0 808.3,128.2 814.2,124.5 824.6,122.6 839.6,122.6 839.7,122.6 840.2,122.6 848.8,124.5 850.4,124.5 854.8,124.5 863.5,124.5 875.9,126.3 878.1,126.3 887.8,130.0 889.6,130.0 894.7,130.0 904.7,130.0 913.6,130.0 924.8,126.3 958.0,106.1", "price_change": 3.8, "sentiment_change": 10, "latest_close": 372.6, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}